Lower urinary tract symptoms

Laborie Medical Technologies Invests in Medical Technology Start-Up Bright Uro

Retrieved on: 
목요일, 11월 30, 2023
Incontinence, Urine, Woman, Pressure, Lower urinary tract symptoms, Investor AB, Patient, System, Urethra, LUTS, Urinary incontinence, Standard of care, Test management, Urodynamic testing, Management, Urology, Gleaning

PORTSMOUTH, N.H., Nov. 30, 2023 /PRNewswire/ -- Leading diagnostic and therapeutic medical technology company Laborie Medical Technologies Corp. (Laborie) announced a strategic equity investment in Bright Uro, an early-stage medical technology company headquartered in Irvine, CA.

Key Points: 
  • PORTSMOUTH, N.H., Nov. 30, 2023 /PRNewswire/ -- Leading diagnostic and therapeutic medical technology company Laborie Medical Technologies Corp. (Laborie) announced a strategic equity investment in Bright Uro, an early-stage medical technology company headquartered in Irvine, CA.
  • Founded in 2021, Bright Uro is developing the Glean Urodynamic System™, a wireless, catheter-free, urodynamic monitoring system intended to quantify the pressure characteristics of the lower urinary tract.
  • "We're thrilled to be working with Laborie," says Bright Uro Founder & CEO Derek Herrera.
  • "Laborie looks forward to leveraging our expertise and leadership in the global urodynamics market to support the Bright Uro team," said Michael Frazzette, President & CEO of Laborie Medical Technologies.

Mid America Pet Food Expands Voluntary Recall to Include Additional Dog and Cat Food Products Due to Possible Salmonella Health Risk

Retrieved on: 
목요일, 11월 9, 2023
Abdominal pain, Pet, Vomiting, Human, Diarrhea, Endocarditis, Salmonellosis, Lower urinary tract symptoms, United, Nausea, Fever, Myalgia, Chronic pain, Risk, Animal, Dysentery, Appetite, Arthritis, Vaccine, Salmonella

MOUNT PLEASANT, Texas, Nov. 9, 2023 /PRNewswire/ -- Mid America Pet Food, Mount Pleasant, Texas, is expanding its October 30, 2023, voluntary recall to include additional pet food products, with Best By Dates before 10/31/24, made at its Mount Pleasant facility, due to the products' potential to be contaminated with Salmonella.

Key Points: 
  • MOUNT PLEASANT, Texas, Nov. 9, 2023 /PRNewswire/ -- Mid America Pet Food, Mount Pleasant, Texas, is expanding its October 30, 2023, voluntary recall to include additional pet food products, with Best By Dates before 10/31/24, made at its Mount Pleasant facility, due to the products' potential to be contaminated with Salmonella.
  • Salmonella can affect animals eating the products, and there is risk to humans from handling contaminated pet products, especially if they have not thoroughly washed their hands after having contact with the products or any surfaces exposed to these products.
  • Rarely, Salmonella can result in more serious ailments, including arterial infections, endocarditis, arthritis, muscle pain, eye irritation, and urinary tract symptoms.
  • Voluntarily recalled brands produced at the Mount Pleasant facility include: Victor Super Premium Dog Foods, Wayne Feeds Dog Food, Eagle Mountain Pet Food, and some Member's Mark varieties with Best By Dates before 10/31/24.

New Data Highlight that Early Intervention with the UroLift® System Facilitates Long-Term Outcomes for BPH Patients

Retrieved on: 
수요일, 5월 3, 2023
TURP, University, BPH, AUA, Catheter, PUL, LUTS, International Prostate Symptom Score, Quality of life, American Urological Association, PVR, TFX, Research, Prostate, Prostatic urethral lift, MIST, NYSE, Lower urinary tract symptoms, MD, Patient, Urology, Urinary retention, Annual general meeting, PVP, Cystoscopy, PSA, IPSS, Disease, Medical imaging, Nursing

PUL with the UroLift® System was durable in most subjects at one and five years.

Key Points: 
  • PUL with the UroLift® System was durable in most subjects at one and five years.
  • In surgical therapy patients, procedure complication rates were lowest for the UroLift® System (17%) and highest for Rezūm™ (28%).
  • “As clinicians listen to their patients’ goals, technological advances are allowing them to deliver treatments that reflect those priorities better than ever before.
  • The data presented at AUA reinforce the importance of earlier intervention in BPH and the UroLift® System as an effective and durable BPH solution that improves patients’ quality of life and supports a superior patient experience.”1-3

Urotronic Announces Presentation of Data from Two Clinical Trials Evaluating Optilume® BPH System's Effectiveness and Durability

Retrieved on: 
월요일, 5월 1, 2023
Male, Icahn School of Medicine at Mount Sinai, BPH, Food, AUA, Urethral stricture, CE marking, LUTS, International Prostate Symptom Score, Paclitaxel, Quality of life, American Urological Association, PINNACLE, Food and Drug Administration, Mount Sinai, Sale, MIST, U.S. FDA, High, Lower urinary tract symptoms, Patient, Randomness, Trial of the century, FDA, Urology, IPSS, Medical imaging, Medical device, Pharmaceutical industry, Spirometry

MINNEAPOLIS, May 1, 2023 /PRNewswire/ -- Urotronic, Inc., a Minnesota-based medical device company pioneering the application of its drug-coated balloon technology for use in interventional urology, today announced the presentation of positive data from two clinical trials evaluating the Optilume® BPH System's effectiveness and durability in treating lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). Four-year and 12-month data from the EVEREST and PINNACLE clinical trials were presented by Dr. Steven A. Kaplan, professor of urology at the Icahn School of Medicine at Mount Sinai in New York and the principal investigator of the two studies, during the American Urological Association's (AUA) Annual Meeting in Chicago.

Key Points: 
  • "The positive data from the PINNACLE and EVEREST trials – including the highest reported Qmax in BPH MIST trials to date – demonstrates clear and compelling sustained clinical outcomes through four years post-treatment," said Dr. Kaplan.
  • "Optilume BPH is not your grandfather's BPH balloon – it's the next generation of minimally invasive technology, creating a new drug device space among BPH therapies."
  • Mechanical dilation with Optilume BPH achieves an anterior commissurotomy, while delivery of paclitaxel is intended to maintain luminal patency during healing.
  • The highest average peak urinary flow rate (Qmax) at 12 months reported in randomized MIST trials for BPH.

Olympus Highlights Minimally Invasive Treatment Options at AUA

Retrieved on: 
월요일, 4월 24, 2023
Science, ASC, Elective surgery, Mini, CMS, Suction, OPPS, Centers for Medicare & Medicaid Services, Urine, Cancer, BPH, AUA, University of Michigan Institute for Social Research, PUL, Olympus, Center for Medicare and Medicaid Innovation, American Urological Association, Bladder cancer, Prostatic urethral lift, Urinary tract infection, Quality of life, Olympus Corporation, Multimedia, Endoscopy, Prostate, Medicare, Plasma, Lower urinary tract symptoms, Patient, Blood, Kidney, Prospective payment system, APC, Safety, Laparoscopy, Medical device, Birth control, Health insurance, Online shopping

CENTER VALLEY, Pa., April 24, 2023 /PRNewswire/ -- Olympus Corporation, a global medical technology company committed to making people's lives healthier, safer, and more fulfilling, will highlight its minimally invasive portfolio for the treatment of enlarged prostate, urinary stones and bladder cancer during the American Urology Association (AUA) annual meeting April 28-May 1 in Chicago.

Key Points: 
  • The Olympus booth will feature hands-on demonstrations of:
    ShockPulse-SE™ system, SOLTIVE™ Premium SuperPulsed Laser System and EMPOWER™ laser for kidney and bladder stone management.
  • A versatile electrode portfolio for plasma resection and vaporization for the treatment of BPH and bladder tumors, including the PlasmaButton™ and PlasmaLoop™ electrodes.
  • Olympus will also highlight its expanded stone management portfolio, including the Mini-PCNL system and new stone retrieval baskets.
  • Visit the Olympus booth, #3015, during AUA and the urology product page for information on the complete urology portfolio.

Belgian Company Minze Health Raises €3.9m to Further Scale Its Digital Health Solutions for the Treatment of Urinary Tract Problems

Retrieved on: 
목요일, 12월 1, 2022
Managed Care, Men, Other Health, General Health, Internet, Consumer, Apps, Applications, Technology, Medical Devices, Biotechnology, Women, Seniors, Health, Growth, Urinary incontinence, RPM, LUTS, Digital, Pelvic floor, New Senior Investment Group, Prevalence, AI, Multimedia, Hospital, Medtech, Patient, Executive Committee, Social Problems, Ageing, Prostate, PMV, Capricorn, Health, Therapy, Quality of life, Lower urinary tract symptoms, Remote patient monitoring, Worldwide, Health insurance, Medical device, Online shopping, Nirmal Minz

View the full release here: https://www.businesswire.com/news/home/20221201005062/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20221201005062/en/
    Minze Diary, a novel and automated bladder diary enabling quicker and better treatment of LUTS.
  • (Photo: Minze Diary)
    Minze Health is a digital healthcare scale-up that enables better care for 2.3 billion people with Lower Urinary Tract Symptoms (LUTS).
  • Most common symptoms are urinary incontinence, a weak urine stream due to an enlarged prostate, frequent voiding and night voiding.
  • Tine Bekaert, Senior Investment Manager at PMV: Minze Healths solutions to often unspoken social problems, represent enormous international potential.

Global Benign Prostatic Hyperplasia Therapeutics Market to 2030 - Increasing Awareness Toward Urological Disorders is Driving Growth - ResearchAndMarkets.com

Retrieved on: 
월요일, 6월 27, 2022
Health, General Health, Ageing, Nocturia, Urinary tract infection, Patient, Man, Population, Exercise, Urine, Growth, Erectile dysfunction, Kidney, Disease, BPH, Type 2 diabetes, Administration for Community Living, Benign prostatic hyperplasia, Urinary retention, Urination, Awareness, Obesity, Woman, Office of Inspector General, U.S. Department of Health and Human Services, Therapy, Stone, U.S. Department of Defense Strategy for Operating in Cyberspace, CAGR, Environment, Semen, Antagonist, Urethra, Male, Prostate, American Urological Association, Quality of life, Human services, Risk, Prostate cancer, Time, Lower urinary tract symptoms, LUTS, Medical imaging, Pharmaceutical industry

The "Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class and Therapy Type: Global Opportunity Analysis and Industry Forecast, 2021-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class and Therapy Type: Global Opportunity Analysis and Industry Forecast, 2021-2030" report has been added to ResearchAndMarkets.com's offering.
  • The global benign prostatic hyperplasia therapeutics market was valued at $5,697.70 million in 2020, and is estimated to reach $9,391.50 million by 2030, growing at a CAGR of 5.00% from 2021 to 2030.
  • Benign prostatic hyperplasia (BPH) is a non-malignant increase in the size of the prostate gland.
  • This report provides an extensive analysis of the current and emerging market trends and dynamics in the global benign prostatic hyperplasia therapeutics market to identify the prevailing opportunities.

Freshpet Voluntarily Recalls One Lot of Freshpet Select Fresh From the Kitchen Home Cooked Chicken Recipe 4.5-pound bags due to Potential Salmonella Contamination.

Retrieved on: 
토요일, 6월 18, 2022
Dysentery, Dog, Lower urinary tract symptoms, Vomiting, Fever, Animal, Walmart, Endocarditis, Arthritis, Salmonellosis, Immunodeficiency, Parent, Human, Salmonella, Appetite, Diarrhea, Sell, Abdominal pain, Nausea, UPC, Irritation, Myalgia, Date, Risk, Vaccine, Freshpet

BETHLEHEM, Pa., June 18, 2022 /PRNewswire/ -- Freshpet Inc. is announcing a voluntary recall of a single lot of Freshpet Select Fresh From the Kitchen Home Cooked Chicken Recipe (4.5 lb.

Key Points: 
  • BETHLEHEM, Pa., June 18, 2022 /PRNewswire/ -- Freshpet Inc. is announcing a voluntary recall of a single lot of Freshpet Select Fresh From the Kitchen Home Cooked Chicken Recipe (4.5 lb.
  • Healthy people infected with Salmonella should monitor themselves for some or all of the following symptoms: nausea, vomiting, diarrhea or bloody diarrhea, abdominal cramping, and fever.
  • Salmonella can result in more serious ailments, including arterial infections, endocarditis, arthritis, muscle pain, eye irritation, and urinary tract symptoms.
  • Please call us if you have any of the recalled product, Freshpet Select Fresh From the Kitchen Home Cooked Chicken Recipe (4.5 lb.

Isracann Biosciences Subsidiary Praesidio Health Submits NPNs to Health Canada

Retrieved on: 
목요일, 5월 19, 2022
NHP, DNA, Company, Cannabis, OTC, Health, Review, Sequela, CSE, Urol, Genetics, NPN, Lower urinary tract symptoms, Health Canada, CMO, Acquisition, GLOBE, MD, Pharmaceutical industry

VANCOUVER, British Columbia, May 19, 2022 (GLOBE NEWSWIRE) -- Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the Company) a multi-faceted organization with a natural health medicine division in Canada and holdings in Israel, is pleased to announce that its wholly owned subsidiary Praesidio Health has completed the natural product number (NPN) submissions to Health Canada for its first formulations.

Key Points: 
  • VANCOUVER, British Columbia, May 19, 2022 (GLOBE NEWSWIRE) -- Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the Company) a multi-faceted organization with a natural health medicine division in Canada and holdings in Israel, is pleased to announce that its wholly owned subsidiary Praesidio Health has completed the natural product number (NPN) submissions to Health Canada for its first formulations.
  • Praesidio Health (https://www.praesidiohealth.com/) is a Canadian medical research company that develops and validates natural health products (NHPs) using an evidence-based process has submitted all first round product formulations to Health Canada for review and approval as natural health products under a class 2 NPN submission.
  • This led to our announcement of March 28, 2022, regarding the acquisition of Praesidio Health Inc.
  • Isracann is a multidisciplinary cannabis focused producer and product developer with Israeli-based cannabis production farm assets and a Canadian natural health medicine development and production arm.

Study Results Show Long-term Efficacy of iTind Procedure

Retrieved on: 
수요일, 5월 18, 2022
Urination, Laparoscopy, Olympus, Quality of life, Quality, Blood, Urine, Time-invariant system, Multimedia, Patient, Prostate, View, BPH, International Prostate Symptom Score, Clinical study design, Treatment, Endoscopy, Urology, DOI, EMEA, IPSS, Man, Lower urinary tract symptoms, AUA, University, Ageing, Olympus Corporation, Urinary tract infection, MD, University of Turin, Medical imaging, Medical device

CENTER VALLEY, Pa. and HAMBURG, Germany, May 18, 2022 /PRNewswire/ -- Olympus, a leading global medtech company providing innovative solutions for medical and surgical procedures, announced today the summary results of a follow-up study to measure the durability of the iTind™ procedure for treating the lower urinary tract symptoms caused by BPH (benign prostatic hyperplasia). The abstract was presented at the American Urological Association Annual Meeting (AUA) on May 15, 2022.1

Key Points: 
  • "The data demonstrate that the iTind procedure is a safe and effective treatment for BPH symptoms that is durable over time."
  • "These study results are highly anticipated by urologists, which was confirmed by the high interest in the iTind device at the Olympus booth at the 2022 AUA meeting," said Vanessa Malka, Executive Director and iTind Commercial Head for Olympus Corporation.
  • "The results demonstrate that the iTind procedure is an alternative to current BPH therapies.
  • More information about the iTind procedure in the U.S. is available at BPHTherapy.com/iTind and in the EMEA region at olympus-europa.com/medical/en/Products-and-Solutions/Products/Product/iTind.html .